Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial. Harding, J. J., Cleary, J. M., Quinn, D. I., Brana, I., Moreno, V., Borad, M. J., Loi, S., Spanggaard, I., Park, H., Ford, J. M., Arnedos, M., Stemmer, S. M., De La Fouchardiere, C., Ramirez, S., Fountzilas, C., Zhang Jie, Xu Feng, Lalani, A. S., Piha-Paul, S., Abou-Alfa, G. K. LIPPINCOTT WILLIAMS & WILKINS. 2021

View details for DOI 10.1200/JCO.2021.39.3_suppl.320

View details for Web of Science ID 000636712800337